CY1111359T1 - Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer - Google Patents

Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer

Info

Publication number
CY1111359T1
CY1111359T1 CY20111100011T CY111100011T CY1111359T1 CY 1111359 T1 CY1111359 T1 CY 1111359T1 CY 20111100011 T CY20111100011 T CY 20111100011T CY 111100011 T CY111100011 T CY 111100011T CY 1111359 T1 CY1111359 T1 CY 1111359T1
Authority
CY
Cyprus
Prior art keywords
mild
memantine
treatment
moderate alzheimer
disease
Prior art date
Application number
CY20111100011T
Other languages
English (en)
Inventor
Scott Mcdonald
Ivan Gergel
Albrecht STÖFFLER
Hans-Joerg Moebius
Yvonne Wirth
Steven Potkin
Original Assignee
Merz Pharma Gmbh & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34798833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111359(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co. Kgaa filed Critical Merz Pharma Gmbh & Co. Kgaa
Publication of CY1111359T1 publication Critical patent/CY1111359T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Η παρούσα εφεύρεση παρέχει μέθοδο για την θεραπεία, πρόληψη ή καθυστέρηση προόδου ήπιας ή ήπιας έως μέτριας ασθένειας Alzheimer, με χορήγηση αποτελεσματικής δόσης μεμαντίνης. Η παρούσα εφεύρεση επίσης παρέχει μέθοδο για αποτροπή της μείωσης στον μεταβολισμό γλυκόζης στις φλοιικές και υπο-φλοιικές περιοχές του εγκεφάλου σε υποκείμενα με ήπια ή ήπια έως μέτρια ασθένεια Alzheimer.
CY20111100011T 2004-01-05 2011-01-04 Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer CY1111359T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53455304P 2004-01-05 2004-01-05
US54217604P 2004-02-04 2004-02-04
EP05711256A EP1703902B1 (en) 2004-01-05 2005-01-05 Memantine for the treatment of mild-to-moderate alzheimer's disease

Publications (1)

Publication Number Publication Date
CY1111359T1 true CY1111359T1 (el) 2015-08-05

Family

ID=34798833

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100011T CY1111359T1 (el) 2004-01-05 2011-01-04 Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer

Country Status (17)

Country Link
US (2) US20060020042A1 (el)
EP (1) EP1703902B1 (el)
AT (1) ATE486592T1 (el)
AU (1) AU2005204358B2 (el)
CA (1) CA2551689A1 (el)
CY (1) CY1111359T1 (el)
DE (1) DE602005024511D1 (el)
DK (1) DK1703902T3 (el)
HR (1) HRP20110035T1 (el)
IL (1) IL176689A0 (el)
NZ (1) NZ548327A (el)
PL (1) PL1703902T3 (el)
PT (1) PT1703902E (el)
RS (1) RS51540B (el)
RU (1) RU2371173C2 (el)
SI (1) SI1703902T1 (el)
WO (1) WO2005067908A2 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
DK1874282T3 (da) 2005-04-06 2010-10-25 Adamas Pharmaceuticals Inc Fremgangsmåder og præparater til behandling af CNS lidelser
AU2006261082B2 (en) * 2005-06-22 2012-04-19 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
US8633201B2 (en) * 2006-04-07 2014-01-21 Boehringer Ingelheim International Gmbh Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
AU2007286855A1 (en) * 2006-08-21 2008-02-28 Novartis Ag Biomarkers for Alzheimer's Disease progression
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
WO2009065596A2 (en) * 2007-11-22 2009-05-28 Develogen Aktiengesellschaft Use of mnk inhibitors for the treatment of alzheimer's disease
UY32072A (es) 2008-08-26 2010-03-26 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmacéuticas
TWI517850B (zh) 2009-09-30 2016-01-21 Ｖｔｖ治療有限責任公司 經取代之咪唑衍生物及其使用方法
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
WO2011104334A1 (en) * 2010-02-26 2011-09-01 Boehringer Ingelheim International Gmbh 4 - [cycloalkyloxy (hetero) arylamino] thieno [2, 3 - d] pyrimidines having mnkl/ mnk2 inhibiting activity for pharmaceutical compositions
AU2011219764A1 (en) * 2010-02-26 2012-08-16 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
US20140350380A1 (en) * 2011-09-19 2014-11-27 The Feinstein Institute For Medical Research Identification and uses of brain activity networks
JP5404750B2 (ja) * 2011-11-22 2014-02-05 シャープ株式会社 認知症ケア支援方法、認知症情報出力装置、認知症ケア支援システム、及びコンピュータプログラム
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2014015047A1 (en) 2012-07-17 2014-01-23 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
EP3019865A4 (en) * 2013-07-12 2017-04-05 Immuneering Corporation Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
EP3864008A1 (en) 2018-10-10 2021-08-18 vTv Therapeutics LLC Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine
CN113631563A (zh) * 2019-01-25 2021-11-09 布朗大学 用于治疗、预防或逆转年龄相关炎症和疾病的组合物和方法
US20210002650A1 (en) * 2019-07-03 2021-01-07 University Of Virginia Patent Foundation Compositions and methods for treating alzheimer's disease
KR102271305B1 (ko) * 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
BR112023001663A2 (pt) 2020-07-29 2023-02-23 Novamedica Llc Composição farmacêutica compreendendo memantina e citicolina
KR102272907B1 (ko) * 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
WO2023248206A1 (en) * 2022-06-24 2023-12-28 Aribio Co., Ltd. Compositions and methods for preventing and treating neurodegenerative diseases
WO2024003784A1 (en) * 2022-06-29 2024-01-04 Aribio Co., Ltd. Composition for preventing and treating neurodegenerative diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES413944A1 (es) * 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) * 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
EP0392059B1 (de) * 1989-04-14 1993-09-15 Merz & Co. GmbH & Co. Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5958919A (en) * 1996-09-20 1999-09-28 Washington University Treatment of presymptomatic alzheimer's disease to prevent neuronal degeneration
UA61962C2 (uk) * 1997-06-30 2003-12-15 Мерц Фарма Гмбх Унд Ко. Кгаа Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
US20040102525A1 (en) * 2002-05-22 2004-05-27 Kozachuk Walter E. Compositions and methods of treating neurological disease and providing neuroprotection
AU2003227516B2 (en) * 2002-05-31 2008-03-20 H. Lundbeck A/S A combination of an NMDA-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
US20040087658A1 (en) * 2002-10-24 2004-05-06 Hans-Joerg Moebius Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders

Also Published As

Publication number Publication date
RS51540B (en) 2011-06-30
SI1703902T1 (sl) 2011-02-28
WO2005067908A2 (en) 2005-07-28
US20100048726A1 (en) 2010-02-25
EP1703902A2 (en) 2006-09-27
CA2551689A1 (en) 2005-07-28
PL1703902T3 (pl) 2011-04-29
IL176689A0 (en) 2006-10-31
EP1703902B1 (en) 2010-11-03
NZ548327A (en) 2009-06-26
AU2005204358A1 (en) 2005-07-28
HRP20110035T1 (hr) 2011-02-28
DK1703902T3 (da) 2011-02-14
AU2005204358B2 (en) 2008-09-04
RU2007129842A (ru) 2009-02-10
US20060020042A1 (en) 2006-01-26
PT1703902E (pt) 2010-11-17
DE602005024511D1 (de) 2010-12-16
ATE486592T1 (de) 2010-11-15
RU2371173C2 (ru) 2009-10-27
WO2005067908A3 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
CY1111359T1 (el) Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer
EA200700427A1 (ru) Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
WO2005076819A3 (en) Chlorite in the treatment of neurodegenerative disease
WO2004001383A3 (en) Safe and effective nutritional supplement formulatins and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
WO2006020581A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) Prevention and treatment of synucleinopathic disease
TW200716208A (en) Modified and immediate release memantine bead formulation
MX2011001384A (es) Composiciones y metodos para tratar trastornos psiquiatricos.
HK1086186A1 (en) Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain
BR0104830A (pt) Tratamento de combinação para a demência ou déficits cognitivos associados com a doença de alzheimer e com a doença de parkinson
TW200740452A (en) Therapeutic gastrodia extracts
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
DE602004008658D1 (de) Behandlung neurodegenerativer krankheiten
JP2018502884A5 (el)
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
BR0308753A (pt) Método para produzir pseudo-ilhotas
BRPI0514303A (pt) composição farmacêutica e método para tratar distúrbios neurodegenerativos
TR201900152T4 (tr) Sinükleinopatik ve amiloidojenik hastalıkların önlenmesi ve tedavisi.
BRPI0402756A (pt) método para o tratamento de distúrbios cognitivos